Global Prevalence and Major Risk Factors of Diabetic Retinopathy
Open accessThe DOI matches its Crossref record; 37 of the 38 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To examine the global prevalence and major risk factors for diabetic retinopathy (DR) and vision-threatening diabetic retinopathy (VTDR) among people with diabetes. RESEARCH DESIGN AND METHODS: A pooled analysis using individual participant data from population-based studies around the world was performed. A systematic literature review was conducted to identify all population-based studies in general populations or individuals with diabetes who had ascertained DR from retinal photographs. Studies provided data for DR end points, including any DR, proliferative DR, diabetic macular edema, and VTDR, and also major systemic risk factors. Pooled prevalence estimates were directly age-standardized to the 2010 World Diabetes Population aged 20–79 years. RESULTS: A total of 35 studies (1980–2008) provided data from 22,896 individuals with diabetes. The overall prevalence was 34.6% (95% CI 34.5–34.8) for any DR, 6.96% (6.87–7.04) for proliferative DR, 6.81% (6.74–6.89) for diabetic macular edema, and 10.2% (10.1–10.3) for VTDR. All DR prevalence end points increased with diabetes duration, hemoglobin A1c, and blood pressure levels and were higher in people with type 1 compared with type 2 diabetes. CONCLUSIONS: There are approximately 93 million people with DR, 17 million with proliferative DR, 21 million with diabetic macular edema, and 28 million with VTDR worldwide. Longer diabetes duration and poorer glycemic and blood pressure control are strongly associated with DR. These data highlight the substantial worldwide public health burden of DR and the importance of modifiable risk factors in its occurrence. This study is limited by data pooled from studies at different time points, with different methodologies and population characteristics.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The prognosis for retaining vision has improved dramatically over the past 40 years owing to improved metabolic and BP control.78,432,488–490”
From American Association of Clinical Endocrinology Clinical Practice Guideline: Developing a Diabetes Mellitus Comprehensive Care Plan-2022 Update. (2022) · cites this paper as [488]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities, and study methodologies33.”
From Economic evaluation for medical artificial intelligence: accuracy vs. cost-effectiveness in a diabetic retinopathy screening case (2024) · cites this paper as [33]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Patients diagnosed with kidney disease, hypertension, and covered under Medicaid insurance are at higher risk for poor visual outcomes13–24.”
From Autonomous AI-assisted diabetic retinopathy screening at primary care is associated with increased presentation to eye care by at risk patients (2026) · cites this paper as [13]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Diabetic retinopathy (DR) is the leading cause of blindness among working-aged adults and early detection is critical for timely management to prevent vision loss1,2.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
The cited source says what the claim attributes to it.
In the citing paper
“Artificial intelligence (AI) is an accurate screening tool for diabetic retinopathy (DR), the leading cause of blindness among working-aged adults.”
From Referral uptake after diabetic retinopathy screening with artificial intelligence-assisted care pathways: a systematic review and meta-analysis (2026) · cites this paper as [2]
2 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
International Diabetes Federation 2017
Carracher, A. M., Marathe, P. H., & Close, K. L. (2018) · Journal of Diabetes · doi:10.1111/1753-0407.12644 · Cited by 13,418
Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802987 · Cited by 7,397
Global estimates of the prevalence of diabetes for 2010 and 2030
Shaw, J. E., Sicree, R. A., & Zimmet, P. Z. (2010) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2009.10.007 · Cited by 7,216
Self-citationColhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., W Neil, H. A., Livingstone, S. J., Thomason, M. J., Mackness, M. I., Charlton-Menys, V., & Fuller, J. H. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16895-5 · Cited by 3,755 · cited 1×
“Statins, however, did not affect DR severity in the few studies in which this was evaluated, although not as a primary outcome (35,36).”
Prevalence of Diabetes among Men and Women in China
Yang, W., Lu, J., Weng, J., Jia, W., Ji, L., Xiao, J., Shan, Z., Liu, J., Tian, H., Ji, Q., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908292 · Cited by 3,031
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885 · cited 1×
“We showed that the prevalence of DR is substantially higher in type 1 than in type 2 diabetes (11,37), an outcome independent of diabetes duration.”
Self-citationKlein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030405011 · Cited by 1,477 · cited 1×
“If data on age at diagnosis of diabetes were available in these studies, participants were classified as type 1 if they were diagnosed before age 30 years and as type 2 if they were diagnosed with diabetes after age 30 years, as previously used in one study (7).”
Self-citationKlein, R., Klein, B. E. K., Moss, S. E., & Linton, K. L. P. (1992) · Ophthalmology · doi:10.1016/s0161-6420(92)32011-1 · Cited by 1,340
Self-citation
Cited by
Items 401–500 of 1,029
The War on Diabetic Retinopathy: Where Are We Now?
Wong, T. Y., & Sabanayagam, C. (2019) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000267 · Cited by 84
“However, a systematic review of 72 studies concluded that DR prevalence may actually be higher in Asian countries and previously reported lower rates could be because of lower rate of detection of DR.7 In Singapore, prevalence of DR and VTDR was higher (33.9%, 8.9”
BackgroundSelf-citationCheng, Y., Yu, X., Zhang, J., Chang, Y., Xue, M., Li, X., Lu, Y., Li, T., Meng, Z., Su, L., et al. (2019) · Diabetologia · doi:10.1007/s00125-019-4838-9 · Cited by 84
Li, P., & Fan, H. (2023) · Cells · doi:10.3390/cells12151931 · Cited by 86
Body mass index and risk of diabetic retinopathy: A meta-analysis and systematic review
Zhou, Y., Zhang, Y., Shi, K., & Wang, C. (2017) · Medicine · doi:10.1097/md.0000000000006754 · Cited by 101
Awareness of diabetic retinopathy among people with diabetes in Jeddah, Saudi Arabia
Alzahrani, S. H., Bakarman, M. A., Al‐Qahtani, S. M., Alqahtani, M. S., Butt, N. S., Salawati, E. M., Alkatheri, A., Malik, A. A., & Saad, K. (2018) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/2042018818758621 · Cited by 84
Sun, L., Wang, R., Hu, G., Liu, H., Lv, K., Duan, Y., Shen, N., Wu, J., Hu, J., Liu, Y., et al. (2021) · Experimental Eye Research · doi:10.1016/j.exer.2021.108718 · Cited by 85
Kumar, Y., & Gupta, S. (2022) · Archives of Computational Methods in Engineering · doi:10.1007/s11831-022-09807-7 · Cited by 91
Artificial Intelligence in Diabetic Eye Disease Screening
(2019) · Asia-Pacific Journal of Ophthalmology · doi:10.22608/apo.201976 · Cited by 82
Self-citationYin, Y., Chen, F., Wang, W., Wang, H., & Zhang, X. (2017) · PubMed Central · Cited by 115
Self-citationMatsuda, S., Tam, T., Singh, R. P., Kaiser, P. K., Petkovsek, D. S., Carneiro, G., Zanella, M. T., & Ehlers, J. P. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.11.009 · Cited by 86
“Diabetes mellitus (DM) is a chronic metabolic disease that has reached epidemic proportions with approximately 285 million individuals affected worldwide (Yau et al., 2012).”
BackgroundTracey, M., Gilmartin, M., O’Neill, K., Fitzgerald, T., McHugh, S., Buckley, C. M., Canavan, R. J., & Kearney, P. M. (2015) · BMC Public Health · doi:10.1186/s12889-016-2818-2 · Cited by 97
“[49].”
Nrf2 as molecular target for polyphenols: A novel therapeutic strategy in diabetic retinopathy
Nabavi, S. F., Barber, A. J., Spagnuolo, C., Russo, G. L., Daglia, M., Nabavi, S. M., & Sobarzo-Sánchez, E. (2016) · Critical Reviews in Clinical Laboratory Sciences · doi:10.3109/10408363.2015.1129530 · Cited by 78
Lim, H. B., Shin, Y. I., Lee, M. W., Park, G. S., & Kim, J. (2019) · JAMA Ophthalmology · doi:10.1001/jamaophthalmol.2019.2537 · Cited by 91
Evidence‐based Danish guidelines for screening of diabetic retinopathy
Grauslund, J., Andersen, N., Andresen, J., Flesner, P., Haamann, P., Heegaard, S., Larsen, M., Laugesen, C. S., Schielke, K. C., Skov, J., et al. (2018) · Acta Ophthalmologica · doi:10.1111/aos.13936 · Cited by 82
Self-citationMostafa, M., Fatease, A. M. A., Alany, R. G., & Abdelkader, H. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061746 · Cited by 87
Moon, J. S., Kang, S., Choi, J. H., Lee, K. A., Moon, J. H., Chon, S., Kim, D. J., Kim, H. J., Seo, J. A., Kim, M. K., et al. (2024) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2024.0249 · Cited by 90
Corticosteroid Use for Diabetic Macular Edema: Old Fad or New Trend?
Stewart, M. W. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0281-8 · Cited by 81
Lamparter, J., Raum, P., Pfeiffer, N., Pető, T., Höhn, R., Elflein, H. M., Wild, P. S., Schulz, A., Schneider, A., & Mirshahi, A. (2014) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2014.02.008 · Cited by 88
“Furthermore, our results canbe compared to several previous studies on the prevalence of diabetic retinopathy as several epidemiological studies have assessed under similar conditions (Yau et al., 2012; Zhang et al., 2010).”
ResultKowluru, R. A. (2013) · Current Medicinal Chemistry · doi:10.2174/09298673113209990029 · Cited by 85
Therapeutic medications against diabetes: What we have and what we expect
Hu, C., & Jia, W. (2018) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2018.11.008 · Cited by 89
Type 2 Diabetes Research Yield, 1951-2012: Bibliometrics Analysis and Density-Equalizing Mapping
Geaney, F., Scutaru, C., Kelly, C. B., Glynn, R. W., & Perry, I. J. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133009 · Cited by 82
Chakravarthy, U., Taylor, S. R. J., Koch, F., Sousa, J. P. C., & Bailey, C. (2018) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2018-312284 · Cited by 80
Role of Inflammation in Classification of Diabetic Macular Edema by Optical Coherence Tomography
Chung, Y.-R., Kim, Y. H., Ha, S. J., Byeon, H.-E., Cho, C., Kim, J. H., & Lee, K. (2019) · Journal of Diabetes Research · doi:10.1155/2019/8164250 · Cited by 80
Bajwa, A., Nosheen, N., Talpur, K. I., & Akram, S. (2023) · Diagnostics · doi:10.3390/diagnostics13030393 · Cited by 80
“It is estimated that more than 200 million people will be affected by DR in 2040 [1].”
BackgroundBody Mass Index: A Risk Factor for Retinopathy in Type 2 Diabetic Patients
Kaštelan, S., Tomić, M., Antunica, A. G., Ljubić, S., Rabatić, J. S., & Karabatić, M. (2013) · Mediators of Inflammation · doi:10.1155/2013/436329 · Cited by 91
“According to a study conducted to estimate the global prevalence of DR, 35% of people with diabetes had some form of DR, 7% had PDR, 7% had DME whilst 10% had vision threatening DR, defined as the presence of PDR and/or DME [40].”
for the International Retina Group, Busch, C., Fraser‐Bell, S., Iglicki, M., Lupidi, M., Couturier, A., Chaikitmongkol, V., Giancipoli, E., Rodríguez‐Valdés, P. J., Gabrielle, P., et al. (2019) · Acta Diabetologica · doi:10.1007/s00592-019-01416-4 · Cited by 79
Self-citationSmartphone-Based Fundus Imaging–Where Are We Now?
Wintergerst, M. W. M., Jansen, L. G., Holz, F. G., & Finger, R. P. (2020) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000303 · Cited by 86
Diabetic Retinopathy: Role of Neurodegeneration and Therapeutic Perspectives
Simó, R., Simó‐Servat, O., Bogdanov, P. M., & Hernández, C. (2022) · Asia-Pacific Journal of Ophthalmology · doi:10.1097/apo.0000000000000510 · Cited by 85
The Association of Estimated Glomerular Filtration Rate With Diabetic Retinopathy and Macular Edema
Man, R. E. K., Sasongko, M. B., Wang, J. J., MacIsaac, R. J., Wong, T. Y., Sabanayagam, C., & Lamoureux, E. L. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-16987 · Cited by 79
Self-citationSirdah, M. M. (2014) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2014.05.001 · Cited by 85
A novel device for accurate and efficient testing for vision-threatening diabetic retinopathy
Maa, A. Y., Feuer, W. J., Davis, C. Q., Pillow, E. K., Brown, T. D., Caywood, R. M., Chasan, J. E., & FRANSEN, S. R. (2015) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2015.12.005 · Cited by 84
“Diabetic retinopathy (DR) remains the leading cause of blindness among working age adults in the US (American Academy of Ophthalmology Retina/Vitreous Panel, 2014; Centers for Disease Control and Prevention, 2011) and is a major cause of blindness worldwide (Yau et al., 2012).”
Mahmoud, A. M., El-Twab, S. M. A., & Abdel-Reheim, E. S. (2016) · European Journal of Nutrition · doi:10.1007/s00394-016-1214-0 · Cited by 83
“6 % of all diabetic patients have some forms of DR [2].”
Chitinase 3 Like-1: An Emerging Molecule Involved in Diabetes and Diabetic Complications
Di Rosa, M., & Malaguarnera, L. (2016) · Pathobiology · doi:10.1159/000444855 · Cited by 75
A Review on Cellular and Molecular Mechanisms Linked to the Development of Diabetes Complications
Babel, R. A., & Dandekar, M. P. (2020) · Current Diabetes Reviews · doi:10.2174/1573399816666201103143818 · Cited by 97
Targeting Tie2 for Treatment of Diabetic Retinopathy and Diabetic Macular Edema
Campochiaro, P. A., & Peters, K. G. (2016) · Current Diabetes Reports · doi:10.1007/s11892-016-0816-5 · Cited by 83
Palochak, C. M. A., Lee, H. E., Song, J., Geng, A., Linsenmeier, R. A., Burns, S. A., & Fawzi, A. A. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8081165 · Cited by 80
Artificial intelligence-based screening for diabetic retinopathy at community hospital
He, J., Cao, T., Xu, F., Wang, S., Tao, H., Wu, T., Sun, L., & Chen, J. (2019) · Eye · doi:10.1038/s41433-019-0562-4 · Cited by 84
“Diabetic retinopathy (DR), a common retinal microvascular complication of diabetes mellitus (DM), is a leading cause of vision loss in the working-age population globally [1].”
BackgroundHassan, B., Qin, S., Ahmed, R., Hassan, T., Taguri, A. H., Hashmi, S. K., & Werghi, N. (2021) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2021.104727 · Cited by 78
Neurovascular regulation in diabetic retinopathy and emerging therapies
Ji, L., Tian, H., Webster, K. A., & Li, W. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-021-03893-9 · Cited by 79
Neurovascular Unit: A New Target for Treating Early Stages of Diabetic Retinopathy
Simó, R., Simó‐Servat, O., Bogdanov, P. M., & Hernández, C. (2021) · Pharmaceutics · doi:10.3390/pharmaceutics13081320 · Cited by 81
Maurissen, T. L., Spielmann, A. J., Schellenberg, G., Bickle, M., Vieira, J. R., Lai, S. Y., Pavlou, G., Fauser, S., Westenskow, P. D., Kamm, R. D., et al. (2024) · Nature Communications · doi:10.1038/s41467-024-45456-z · Cited by 82
“17 and 18).”
Hautala, N., Aikkila, R., Korpelainen, J., Keskitalo, A., Kurikka, A., Falck, A., Bloigu, R., & Alanko, H. (2014) · Acta Ophthalmologica · doi:10.1111/aos.12278 · Cited by 77
“The global prevalence of type 2 diabetes has been increasing in an exponential manner, and current projections estimate that 439 million adults will be affected by 2030 (Shaw et al. 2010; Yau et al. 2012).”
BackgroundWang, Y., Liu, C., Hu, W., Luo, L., Shi, D., Zhang, J., Yin, Q., Zhang, L., Han, X., & He, M. (2024) · npj Digital Medicine · doi:10.1038/s41746-024-01032-9 · Cited by 76
“Globally, the overall prevalence of referable DR has been estimated to be around 10%, but this varies across geographic regions, ethnicities,andstudymethodologies 33 .”
Deep Learning Predicts OCT Measures of Diabetic Macular Thickening From Color Fundus Photographs
Arcadu, F., Benmansour, F., Maunz, A., Michon, J., Hašková, Z., McClintock, D. E., Adamis, A. P., Willis, J. R., & Prunotto, M. (2019) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.18-25634 · Cited by 80
Deep and Densely Connected Networks for Classification of Diabetic Retinopathy
Riaz, H., Park, J. S., Choi, H., Kim, H., & Kim, J. (2020) · Diagnostics · doi:10.3390/diagnostics10010024 · Cited by 83
“Introduction Diabetic cases, and specifically diabetic retinopathy cases, have been on the rise globally [1] leading to a major cause of blindness for young adults as well as older individuals (20–70 years) [2].”
BackgroundLópez-Contreras, A. K., Martínez-Ruíz, M. G., Olvera-Montaño, C., Robles-Rivera, R. R., Arévalo-Simental, D. E., Castellanos‐González, J. A., Hernández-Chávez, A., Huerta-Olvera, S. G., Cardona-Muñóz, E. G., & Rodríguez-Carrizález, A. D. (2020) · Antioxidants · doi:10.3390/antiox9090891 · Cited by 83
“Among the 468 million people with diabetes mellitus worldwide, approximately 90 million suffer from some form of DR [7].”
BackgroundNew treatments for diabetic retinopathy
Das, A., Stroud, S. R., Mehta, A. M., & Rangasamy, S. (2014) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12384 · Cited by 76
“Diabetic retinopathy, a microvascular complication of diabetes, is prevalent in ∼35% of people with diabetes [2].”
BackgroundVitreous biomarkers in diabetic retinopathy: A systematic review and meta-analysis
McAuley, A. K., Sanfilippo, P. G., Hewitt, A. W., Liang, H. H., Lamoureux, E. L., Wang, J. J., & Connell, P. (2013) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2013.09.010 · Cited by 76
“Approximately one third of adults in the United States of America with DM have DR and a worldwide prevalence of 155 million is expected by 2030 [1, 3].”
BackgroundSelf-citationFully Automatic Segmentation of Fluorescein Leakage in Subjects With Diabetic Macular Edema
Rabbani, H., Allingham, M. J., Mettu, P., Cousins, S. W., & Farsiu, S. (2015) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.14-15457 · Cited by 81
Automated diabetic macular edema (DME) grading system using DWT, DCT Features and maculopathy index
Acharya, U. R., Mookiah, M. R. K., Koh, J. E. W., Tan, J. H., Bhandary, S. V., Rao, A. K., Hagiwara, Y., Chua, C. K., & Laude, A. (2017) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2017.03.016 · Cited by 76
Nrf2 Activation Is a Potential Therapeutic Approach to Attenuate Diabetic Retinopathy
Deliyanti, D., Alrashdi, S. F., Tan, S. M., Meyer, C. J., Ward, K. W., de Haan, J. B., & Wilkinson‐Berka, J. L. (2018) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.17-22920 · Cited by 76
Sensitivity and Specificity of Smartphone-Based Retinal Imaging for Diabetic Retinopathy
Sengupta, S., Sindal, M. D., Baskaran, P., Pan, U., & Venkatesh, R. (2018) · Ophthalmology Retina · doi:10.1016/j.oret.2018.09.016 · Cited by 76
Do Genomic Factors Play a Role in Diabetic Retinopathy?
Cabrera, A. P., Monickaraj, F., Rangasamy, S., Hobbs, S., McGuire, P. G., & Das, A. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9010216 · Cited by 78
“With 35% of the diabetic population afflicted, DR is the most common cause of blindness among middle-aged working adults [5].”
BackgroundRezzola, S., Loda, A., Corsini, M., Semeraro, F., Annese, T., Presta, M., & Ribatti, D. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.581288 · Cited by 82
“Currently, DR affects more than 93 million people in the world with an overall prevalence close to 35% of the diabetic population (3).”
BackgroundHinge attention network: A joint model for diabetic retinopathy severity grading
Shaik, N. S., & Cherukuri, T. K. (2022) · Applied Intelligence · doi:10.1007/s10489-021-03043-5 · Cited by 75
Wykoff, C. C., Chakravarthy, U., Campochiaro, P. A., Bailey, C., Green, K., & Cunha-Vaz, J. G. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.11.034 · Cited by 75
Gene Therapy Intervention in Neovascular Eye Disease: A Recent Update
Lin, F.-L., Wang, P.-Y., Chuang, Y.-F., Wang, J.-H., Wong, V. H. Y., Bui, B. V., & Liu, G.-S. (2020) · Molecular Therapy · doi:10.1016/j.ymthe.2020.06.029 · Cited by 74
Self-citationPrevalence of diabetic retinopathy in Pakistan: A systematic review
Mumtaz, S. N., Fahim, M. F., Arslan, M., Shaikh, S. A., Kazi, U., & Memon, M. S. (2018) · Pakistan Journal of Medical Sciences · doi:10.12669/pjms.342.13819 · Cited by 74
The Benefits of Flavonoids in Diabetic Retinopathy
Matos, A. L., Bruno, D. F., Ambrósio, A. F., & Santos, P. F. (2020) · Nutrients · doi:10.3390/nu12103169 · Cited by 71
“Modifiable risk factors associated with DR include obesity, smoking, hyperglycemia, hypertension and dyslipidemia [7,9].”
BackgroundWu, Y., Xiong, T., Tan, X. W., & Chen, L. (2022) · BMC Medicine · doi:10.1186/s12916-022-02675-9 · Cited by 77
“6% will develop diabetic retinopathy [6], and nearly 50% will develop diabetic neuropathy [7].”
BackgroundCalcium dobesilate for diabetic retinopathy: a systematic review and meta-analysis
Zhang, X., Liu, W., Wu, S., Jin, J., Li, W., & Wang, N. (2014) · Science China Life Sciences · doi:10.1007/s11427-014-4792-1 · Cited by 74
Self-citationDiabetic macular oedema: pathophysiology, management challenges and treatment resistance
Bahrami, B., Zhu, M., Hong, T., & Chang, A. (2016) · Diabetologia · doi:10.1007/s00125-016-3974-8 · Cited by 75
“Diabetic macular oedema (DMO) is a leading cause of vision loss and the most common cause of vision loss in diabetic patients, affecting an estimated 21 million people worldwide in 2010 [1, 2].”
BackgroundScreening for diabetic retinopathy using new mydriasis-free, full-field flicker ERG recording device
Fukuo, M., Kondo, M., Hirose, A., Fukushima, H., Ikesugi, K., Sugimoto, M., Kato, K., Uchigata, Y., & Kitano, S. (2016) · Scientific Reports · doi:10.1038/srep36591 · Cited by 79
Mori, Y., Suzuma, K., Uji, A., Ishihara, K., Yoshitake, S., Fujimoto, M., Dodo, Y., Yoshitake, T., Miwa, Y., & Murakami, T. (2016) · Scientific Reports · doi:10.1038/srep39161 · Cited by 74
Ehlers, J. P., Uchida, A., Hu, M., Figueiredo, N., Kaiser, P. K., Heier, J. S., Brown, D. M., Boyer, D. S., Diana, V., Gibson, A., et al. (2019) · Ophthalmology Retina · doi:10.1016/j.oret.2019.06.010 · Cited by 77
The Prevalence of Diabetic Retinopathy in Australian Adults with Self-Reported Diabetes
Keel, S., Xie, J., Foreman, J., van Wijngaarden, P., Taylor, H. R., & Dirani, M. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2017.02.004 · Cited by 73
Self-citationWang, F., Mao, Y., Wang, H., Liu, Y., & Huang, P. (2021) · Clinical Drug Investigation · doi:10.1007/s40261-021-01110-w · Cited by 78
“Diabetic retinopathy (DR) is a common microvascular complication in patients with diabetes and a main cause of blindness worldwide [8].”
BackgroundSakini, A. S. A., Hamid, A. K., Alkhuzaie, Z. A., Al-Aish, S. T., Al-Zubaidi, S., Tayem, A. A., Alobi, M. A., Sakini, A. S. A., Al-Aish, R. T., Al‐Shami, K., et al. (2024) · International Journal of Retina and Vitreous · doi:10.1186/s40942-024-00603-y · Cited by 84
“It was found that about 10.2% of 22,896 diabetic patients had diabetic retinopathy, and 6.81% had DME [3].”
BackgroundInfluentialSasaki, M., Kawasaki, R., Rogers, S., Man, R. E. K., Itakura, K., Xie, J., Flood, V., Tsubota, K., Lamoureux, E., & Wang, J. J. (2015) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.15-17485 · Cited by 70
Self-citationMalik, A. N., Parsade, C. K., Ajaz, S., Crosby‐Nwaobi, R., Gnudi, L., Czajka, A., & Sivaprasad, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.10.006 · Cited by 78
Guo, V. Y., Cao, B., Wu, X., Lee, J. J. W., & Zee, B. C.-Y. (2016) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2016.03.009 · Cited by 77
Awadalla, H., Noor, S. K., Elmadhoun, W. M., Almobarak, A. O., Elmak, N. E., Abdelaziz, S. I., Sulaiman, A. A., & Ahmed, M. H. (2017) · Diabetes & Metabolic Syndrome Clinical Research & Reviews · doi:10.1016/j.dsx.2017.07.039 · Cited by 83
Development of a Deep Learning Algorithm for Automatic Diagnosis of Diabetic Retinopathy
Manoj, R., Pagidimarri, V., Barreto, R., Kadam, A., Kasivajjala, V., & Arun, A. (2017) · Studies in health technology and informatics · doi:10.3233/978-1-61499-830-3-559 · Cited by 73
Cao, D., Yang, D., Yu, H., Xie, J., Zeng, Y., Wang, J., & Zhang, L. (2018) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.13390 · Cited by 81
Self-citationEaton, A. M., Koh, S., Jimenez, J., & Riemann, C. D. (2018) · Ophthalmology and Therapy · doi:10.1007/s40123-018-0155-5 · Cited by 73
for the Ozurdex MEAD Study Group, Augustin, A. J., Kuppermann, B. D., Lanzetta, P., Loewenstein, A., Li, X., Cui, H., Hashad, Y., & Whitcup, S. M. (2015) · BMC Ophthalmology · doi:10.1186/s12886-015-0148-2 · Cited by 72
“vision loss, is estimated to affect 21 million individuals worldwide [1].”
BackgroundSelf-citationPutative protective role of lutein and zeaxanthin in diabetic retinopathy
Neelam, K., Goenadi, C. J., Lun, K., Yip, C. C., & Au Eong, K.-G. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309814 · Cited by 69
Effects of glucose-lowering agents on vascular outcomes in type 2 diabetes: A critical reappraisal
Scheen, A. J., & Charbonnel, B. H. (2014) · Diabetes & Metabolism · doi:10.1016/j.diabet.2014.03.004 · Cited by 76
Dietary natural products as epigenetic modifiers in aging-associated inflammation and disease
Evans, L. W., Stratton, M. S., & Ferguson, B. S. (2020) · Natural Product Reports · doi:10.1039/c9np00057g · Cited by 74
The role of O ‐GlcNAc signaling in the pathogenesis of diabetic retinopathy
Semba, R. D., Hu, H., Lutty, G. A., Eyk, J. E. V., & Hart, G. W. (2014) · PROTEOMICS - CLINICAL APPLICATIONS · doi:10.1002/prca.201300076 · Cited by 81
Screening intervals for diabetic retinopathy and incidence of visual loss: a systematic review
Echouffo-Tcheugui, J. B., Ali, M. K., Roglić, G., Hayward, R. A., & Narayan, K. M. V. (2013) · Diabetic Medicine · doi:10.1111/dme.12274 · Cited by 77
Lian, J. X., Gangwani, R. A., McGhee, S. M., Chan, C. K. W., Lam, C. L. K., Primary Health Care Group, & Wong, D. S. H. (2016) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2015-307382 · Cited by 71
Barcelona, P. F., Sitaras, N., Galán, A., Esquiva, G., Jmaeff, S., Jian, Y., Šarunic, M. V., Cuenca, N., Sapieha, P. S., & Saragovi, H. U. (2016) · Journal of Neuroscience · doi:10.1523/jneurosci.4278-15.2016 · Cited by 72
“into the retina, which can lead to significant decreases in visual acuity (Antonetti et al., 2012; Yau et al., 2012).”
BackgroundLi, Y., Ryu, C. L., Munie, M., Noorulla, S., Rana, S., Edwards, P. A., Gao, H., & Qiao, X. (2018) · Journal of Diabetes Research · doi:10.1155/2018/2801450 · Cited by 78
“The homogeneity in the duration of diabetes and 5-year HbA1c levels among the two groups helped provide a relatively equal comparison regarding the risk factors of DR in this study, since these two clinical parameters are believed to be the most important factors that impact DR progression [14, 17].”
BackgroundThe Role of Osteopontin in Microglia Biology: Current Concepts and Future Perspectives
Rosmus, D.-D., Lange, C., Ludwig, F., Ajami, B., & Wieghofer, P. (2022) · Biomedicines · doi:10.3390/biomedicines10040840 · Cited by 67
“Whereas about 35% of patients suffering from diabetes develop early stages of DR called non-proliferative diabetic retinopathy (NPDR), about 7% progress to the development of proliferative DR (PDR), characterized by the presence of retinal neovascularizations (RNV) in the vitreous cavity [219,220].”
BackgroundThe Diabetic Retinopathy “Pandemic” and Evolving Global Strategies: The 2023 Friedenwald Lecture
Wong, T. Y., & Tan, T. (2023) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.64.15.47 · Cited by 81
“4,6 This pattern of disease progression provides a clear opportunity for early intervention to prevent vision loss in the later stages of disease.”
BackgroundSelf-citationRaum, P., Lamparter, J., Ponto, K. A., Pető, T., Höhn, R., Schulz, A., Schneider, A., Wild, P. S., Pfeiffer, N., & Mirshahi, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0127188 · Cited by 82
“Diabetic retinopathy (DR) is a microangiopathic complication of diabetes mellitus (DM) being associated with cardiovascular risk factors [3,4].”
Vitamin D Deficiency Is Not Associated with Diabetic Retinopathy or Maculopathy
Alam, U., Amjad, Y., Chan, A. W. S., Asghar, O., Petropoulos, I. N., & Malik, R. A. (2016) · Journal of Diabetes Research · doi:10.1155/2016/6156217 · Cited by 71
for the OCEAN study group, Ziemssen, F., Feltgen, N., Holz, F., Guthoff, R., Ringwald, A., Bertelmann, T., Wiedon, A., & Korb, C. A. (2017) · BMC Ophthalmology · doi:10.1186/s12886-017-0401-y · Cited by 71
“1 years, reflecting the established fact that diabetic retinopathies including DME can affect relatively young patients [12].”
BackgroundSelf-citationDifferent lasers and techniques for proliferative diabetic retinopathy
Moutray, T., Evans, J. R., Lois, N., Armstrong, D. J., Pető, T., & Azuara‐Blanco, A. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012314.pub2 · Cited by 72
Vujosevic, S., Toma, C., Villani, E., Gatti, V., Brambilla, M., Muraca, A., Ponziani, M. C., Aimaretti, G., Nuzzo, A., Nucci, P., et al. (2019) · Journal of Diabetes Research · doi:10.1155/2019/2547216 · Cited by 70
“Diabetic retinopathy (DR) is the most important complication of both type 1 and type 2 diabetes mellitus (DM) [1].”
BackgroundPiyasena, M. M. P. N., Murthy, G. V. S., Yip, J. L. Y., Gilbert, C., Peto, T., Gordon, I., Hewage, S., & Kamalakannan, S. (2018) · Systematic Reviews · doi:10.1186/s13643-018-0846-y · Cited by 67
Therapies Based on Nanoparticles for Eye Drug Delivery
Meza-Ríos, A., Navarro‐Partida, J., Armendáriz‐Borunda, J., & Santos, A. (2020) · Ophthalmology and Therapy · doi:10.1007/s40123-020-00257-7 · Cited by 72
Updates on Gene Therapy for Diabetic Retinopathy
Wang, J.-H., Roberts, G. E., & Liu, G. (2020) · Current Diabetes Reports · doi:10.1007/s11892-020-01308-w · Cited by 69
“It is estimated that there are 17 million and 21 million patients with PDR and DME, respectively [6].”
BackgroundSelf-citationXiao, Y., Wei, L., Xiong, X., Yang, M., & Sun, L. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.564738 · Cited by 72
“6 mmol/L; (6) estimated glomerular filtration rate (eGFR) <15 mL/min/1.”
BackgroundYu, X., Ma, X., Lin, W., Xu, Q., Zhou, H., & Kuang, H. (2020) · Experimental Eye Research · doi:10.1016/j.exer.2020.108300 · Cited by 70
Next-generation anti-VEGF agents for diabetic macular oedema
Iglicki, M., González, D. P., Loewenstein, A., & Zur, D. (2021) · Eye · doi:10.1038/s41433-021-01722-8 · Cited by 69
Hu, Y., Xu, Q., Li, H., Meng, Z., Hao, M., Ma, X., Lin, W., & Kuang, H. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.827896 · Cited by 86
M2 microglia-derived exosomes promote vascular remodeling in diabetic retinopathy
Wang, X., Xu, C., Bian, C., Ge, P., Lei, J., Wang, J., Xiao, T., Fan, Y., Gu, Q., Li, H., et al. (2024) · Journal of Nanobiotechnology · doi:10.1186/s12951-024-02330-w · Cited by 74
“Among these, approximately 30% of people have been reported to have varying degrees of visual impairment [1].”
BackgroundSelf-citationSivaprasad, S., Wong, T. Y., Gardner, T. W., Sun, J. K., & Bressler, N. M. (2025) · Nature Reviews Disease Primers · doi:10.1038/s41572-025-00646-x · Cited by 77
“Established risk factors for the development and progression of microvascular changes of the retina to VTDR include increasing duration of diabetes mellitus and suboptimal control of hyperglycaemia and hypertension 5,56 .”
Self-citation
Metadata
- Authors
- Yau, J. W. Y., Rogers, S. L., Kawasaki, R., Lamoureux, E. L., Kowalski, J. W., Bek, T., Chen, S.-J., Dekker, J. M., Fletcher, A., Grauslund, J., Haffner, S., Hamman, R. F., Ikram, M. K., Kayama, T., Klein, B. E. K., Klein, R., Krishnaiah, S., Mayurasakorn, K., O’Hare, J. P., Orchard, T. J., Porta, M., Rema, M., Roy, M. S., Sharma, T., Shaw, J., Taylor, H., Tielsch, J. M., Varma, R., Wang, J. J., Wang, N., West, S., Xu, L., Yasuda, M., Zhang, X., Mitchell, P., Wong, T. Y., & for the Meta-Analysis for Eye Disease (META-EYE) Study Group
- Affiliations
- The University of Melbourne (AU)
- Allergan (United States) (US)
- Aarhus University Hospital (DK)
- Taipei Veterans General Hospital (TW)
- Amsterdam Public Health (NL)
- London School of Hygiene & Tropical Medicine (GB)
- Odense University Hospital (DK)
- Shavano Park, Texas
- Colorado School of Public Health (US)
- Erasmus MC (NL)
- Yamagata University (JP)
- University of Wisconsin–Madison (US)
- L V Prasad Eye Institute (IN)
- Samut Sakhon Hospital (TH)
- University of Warwick (GB)
- University of Pittsburgh (US)
- University of Turin (IT)
- Madras Diabetes Research Foundation (IN)
- Rutgers New Jersey Medical School (US)
- Sankara Nethralaya (IN)
- Baker Heart and Diabetes Institute (AU)
- Johns Hopkins University (US)
- University of Southern California (US)
- The University of Sydney (AU)
- Beijing Tongren Hospital (CN)
- Johns Hopkins Hospital (US)
- Kyushu University (JP)
- Centers for Disease Control and Prevention (US)
- Corresponding author
- Wong, Tien Y.
- ORCID
- Rogers, Sophie L.
- Kawasaki, Ryo
- Lamoureux, Ecosse L.
- Bek, Toke
- Chen, Shih-Jen
- Fletcher, Astrid
- Grauslund, Jakob
- Hamman, Richard F.
- Ikram, M. Kamran
- Klein, Barbara E.K.
- Klein, Ronald
- Krishnaiah, Sannapaneni
- Mayurasakorn, Korapat
- Orchard, Trevor J.
- Porta, Massimo
- Sharma, Tarun
- Shaw, Jonathan
- Taylor, Hugh
- Tielsch, James M.
- Varma, Rohit
- Wang, Jie Jin
- West, Sheila
- Xu, Liang
- Zhang, Xinzhi
- Mitchell, Paul
- Wong, Tien Y.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2012-02-10
- Volume
- 35
- Issue
- 3
- Pages
- 556-564
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- PMC
- PMC3322721
- OpenAlex
- W2138480916
- Cited by
- 4,985
- References
- 38
- Citations by year
- 2026: 374 · 2025: 447 · 2024: 477 · 2023: 429 · 2022: 499 · 2021: 544 · 2020: 520 · 2019: 365 · 2018: 331 · 2017: 305 · 2016: 238 · 2015: 198 · 2014: 139 · 2013: 80 · 2012: 30
- FWCI
- 21.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes Care (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Research Publications (Maastricht University) (publishedVersion, cc-by-nc-nd)
- Pure Amsterdam UMC (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- LSHTM Research Online (London School of Hygiene and Tropical Medicine) (acceptedVersion)
- Minerva Access (University of Melbourne) (submittedVersion, cc-by-nc-nd)
- National University of Singapore (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- RePub (Erasmus University Rotterdam) (submittedVersion, other-oa)
- University of Southern Denmark Research Portal (University of Southern Denmark) (submittedVersion)
- Research Publications (Maastricht University) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- Research to Prevent Blindness
- Hyderabad Eye Research Foundation
- Oogfonds
- Algemene Nederlandse Vereniging ter voorkoming van Blindheid
- National Institutes of Health
- Allergan
- Medical Research Council
- National Eye Institute (EY0-6594, R01 EY 09860, R01EY009860, U10EY006594, R01EY016379)
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Diseases and Treatments
- Health Sciences › Medicine › Radiology, Nuclear Medicine and Imaging › Retinal Imaging and Analysis
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- diabetic retinopathy, vision-threatening diabetic retinopathy, proliferative diabetic retinopathy, diabetic macular edema, global prevalence, risk factors, diabetes duration, glycemic control, HbA1c, blood pressure, type 1 diabetes, type 2 diabetes, fundus images, public health burden
- MeSH terms
- Adult, Aged, Blood Glucose, Blood Pressure, Diabetic Retinopathy, Female, Humans, Male, Middle Aged, Risk Factors, Prevalence, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.